Reducing AB plasma utilisation through the AB plasma appropriateness index.

fresh frozen plasma massive transfusion plasma transfusion quality improvement transfusion medicine trauma utilisation management

Journal

Transfusion medicine (Oxford, England)
ISSN: 1365-3148
Titre abrégé: Transfus Med
Pays: England
ID NLM: 9301182

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 15 06 2019
revised: 17 08 2019
accepted: 19 08 2019
pubmed: 3 10 2019
medline: 1 5 2020
entrez: 3 10 2019
Statut: ppublish

Résumé

We hypothesised that there was inappropriate group AB plasma used in our hospital, identifiable by a novel key quality indicator (KQI) and mitigable through massive transfusion protocol (MTP) modification. Group AB plasma is a scarce resource strained by increasing usage worldwide when used as universal donor plasma in non-group AB patients. To reduce inappropriate use and to promote benchmarking to the best practice, we developed the AB plasma appropriateness index (ABAI). ABAI is the ratio of AB plasma transfused to group AB or unknown blood group patients to all AB plasma utilised, where values closer to 1 are better. Data collected included AB plasma disposition by blood group, indications for transfusion, total blood utilisation, patient clinical characteristics and outcomes. ABAI during a 12-month period was retrospectively assessed, which led to implementation of pre-thawed group A plasma instead of group AB plasma for trauma patients starting in July 2017. The ABAI retrospectively showed inappropriate use in non-group AB patients in our hospital, the majority used to avoid expiry after thaw. When comparing 1-year pre- and post-implementation periods, ABAI improved from 0·464 to 0·900 (P < 0·0001). After exclusion of therapeutic plasma exchange, ABAI still improved (0·486-0·720, P < 0·0001). No differences in the length of stay or mortality associated in 32 patients receiving group A plasma for emergency release were observed. The ABAI is a novel KQI to indicate inappropriate AB plasma usage for quality improvement. This led to thawed A plasma use for MTPs, reducing inappropriate AB plasma usage.

Sections du résumé

OBJECTIVES OBJECTIVE
We hypothesised that there was inappropriate group AB plasma used in our hospital, identifiable by a novel key quality indicator (KQI) and mitigable through massive transfusion protocol (MTP) modification.
BACKGROUND BACKGROUND
Group AB plasma is a scarce resource strained by increasing usage worldwide when used as universal donor plasma in non-group AB patients. To reduce inappropriate use and to promote benchmarking to the best practice, we developed the AB plasma appropriateness index (ABAI). ABAI is the ratio of AB plasma transfused to group AB or unknown blood group patients to all AB plasma utilised, where values closer to 1 are better.
METHODS METHODS
Data collected included AB plasma disposition by blood group, indications for transfusion, total blood utilisation, patient clinical characteristics and outcomes. ABAI during a 12-month period was retrospectively assessed, which led to implementation of pre-thawed group A plasma instead of group AB plasma for trauma patients starting in July 2017.
RESULTS RESULTS
The ABAI retrospectively showed inappropriate use in non-group AB patients in our hospital, the majority used to avoid expiry after thaw. When comparing 1-year pre- and post-implementation periods, ABAI improved from 0·464 to 0·900 (P < 0·0001). After exclusion of therapeutic plasma exchange, ABAI still improved (0·486-0·720, P < 0·0001). No differences in the length of stay or mortality associated in 32 patients receiving group A plasma for emergency release were observed.
CONCLUSION CONCLUSIONS
The ABAI is a novel KQI to indicate inappropriate AB plasma usage for quality improvement. This led to thawed A plasma use for MTPs, reducing inappropriate AB plasma usage.

Identifiants

pubmed: 31576629
doi: 10.1111/tme.12632
doi:

Substances chimiques

ABO Blood-Group System 0

Types de publication

Clinical Trial Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

381-388

Informations de copyright

© 2019 British Blood Transfusion Society.

Références

American Association of Blood Banks. (2014) Association Bulletin #14-02: TRALI Risk Mitigation for Plasma and Whole Blood for Allogeneic Transfusion, 2019.
Apelseth, T.O., Molnar, L., Arnold, E. & Heddle, N.M. (2012) Benchmarking: applications to transfusion medicine. Transfusion Medicine Reviews, 26, 321-332.
Arah, O.A., Westert, G.P., Hurst, J. & Klazinga, N.S. (2006) A conceptual framework for the OECD Health Care Quality Indicators Project. International Journal for Quality in Health Care, 18 (Suppl 1), 5-13.
Berseus, O., Boman, K., Nessen, S.C. & Westerberg, L.A. (2013) Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion, 53(Suppl. 1), 114S-123S.
Chhibber, V., Greene, M., Vauthrin, M., Bailey, J. & Weinstein, R. (2014) Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME). Transfusion, 54, 1751-1755.
Cotton, B.A., Reddy, N., Hatch, Q.M. et al. (2011) Damage control resuscitation is associated with a reduction in resuscitation volumes and improvement in survival in 390 damage control laparotomy patients. Annals of Surgery, 254, 598-605.
Dunbar, N.M., Yazer, M.H. & C. Biomedical Excellence for Safer Transfusion (2016) A possible new paradigm? A survey-based assessment of the use of thawed group A plasma for trauma resuscitation in the United States. Transfusion, 56, 125-129.
Dunbar, N.M., Olson, N.J., Szczepiorkowski, Z.M., Martin, E.D., Tysarcyk, R.M., Triulzi, D.J., Alarcon, L.H. & Yazer, M.H. (2017a) Blood component transfusion and wastage rates in the setting of massive transfusion in three regional trauma centers. Transfusion, 57, 45-52.
Dunbar, N.M., Yazer, M.H. & Biomedical Excellence for Safer Transfusion (BEST) Collaborative and the STAT Study Investigators (2017b) Safety of the use of group A plasma in trauma: the STAT study. Transfusion, 57, 1879-1884.
Eder, A.F., Herron, R.M. Jr., Strupp, A., Dy, B., White, J., Notari, E.P., Dodd, R.Y. & Benjamin, R.J. (2010) Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion, 50, 1732-1742.
Fung, M.K., Grossman, B., Hillyer, C.D. & Westhoff, C. (2014) Technical Manual. American Association of Blood Banks, Bethesda, MD.
Harada, M.Y., Ko, A., Barmparas, G., Smith, E.J., Patel, B.K., Dhillon, N.K., Thomsen, G.M. & Ley, E.J. (2017) 10-year trend in crystalloid resuscitation: reduced volume and lower mortality. International Journal of Surgery, 38, 78-82.
Heelan Gladden, A.A., Peltz, E.D., McIntyre, R.C. Jr., Vega, S., Krell, R., Velopulos, C., Ferrigno, L. & Wright, F.L. (2018) Effect of pre-hospital use of the assessment of blood consumption score and pre-thawed fresh frozen plasma on resuscitation and trauma mortality. Journal of the American College of Surgeons, 228, 141-147.
Holcomb, J.B., del, Junco, D.J., Fox, E.E. et al. (2013) The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surgery, 148, 127-136.
Holcomb, J.B., Tilley, B.C., Baraniuk, S. et al. (2015) Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA, 313, 471-482.
Hommel, I., van, Gurp, P.J., Tack, C.J., Wollersheim, H. & Hulscher, M.E. (2016) Perioperative diabetes care: development and validation of quality indicators throughout the entire hospital care pathway. BMJ Quality and Safety, 25, 525-534.
Isaak, E.J., Tchorz, K.M., Lang, N., Kalal, L., Slapak, C., Khalife, G., Smith, D. & McCarthy, M.C. (2011) Challenging dogma: group A donors as “universal plasma” donors in massive transfusion protocols. Immunohematology, 27, 61-65.
Josephson, C.D., Castillejo, M.I., Grima, K. & Hillyer, C.D. (2010) ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfusion and Apheresis Science, 42, 83-88.
Karafin, M.S., Blagg, L., Tobian, A.A., King, K.E., Ness, P.M. & Savage, W.J. (2012) ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion, 52, 2087-2093.
Kormoczi, G.F., Saemann, M.D., Buchta, C. et al. (2006) Influence of clinical factors on the haemolysis marker haptoglobin. European Journal of Clinical Investigation, 36, 202-209.
Lauzier, F., Cook, D., Griffith, L., Upton, J. & Crowther, M. (2007) Fresh frozen plasma transfusion in critically ill patients. Critical Care Medicine, 35, 1655-1659.
Ley, E.J., Clond, M.A., Srour, M.K., Barnajian, M., Mirocha, J., Margulies, D.R. & Salim, A. (2011) Emergency department crystalloid resuscitation of 1.5 L or more is associated with increased mortality in elderly and nonelderly trauma patients. The Journal of Trauma, 70, 398-400.
McWilliams, B., Yazer, M.H., Cramer, J., Triulzi, D.J. & Waters, J.H. (2012) Incomplete pretransfusion testing leads to surgical delays. Transfusion, 52, 2139-2144.
Meyer, D.E., Vincent, L.E., Fox, E.E., O'Keeffe, T., Inaba, K., Bulger, E., Holcomb, J.B. & Cotton, B.A. (2017) Every minute counts: time to delivery of initial massive transfusion cooler and its impact on mortality. Journal of Trauma and Acute Care Surgery, 83, 19-24.
Robinson, B.R., B.A. Cotton, T.A. Pritts, R. Branson, J.B. Holcomb, P. Muskat, E.E. Fox, C.E. Wade, D.J. del Junco, E.M. Bulger, M.J. Cohen, M.A. Schreiber, J.G. Myers, K.J. Brasel, H.A. Phelan, L.H. Alarcon, M.H. Rahbar, R.A. Callcut and P.s. group (2013). Application of the Berlin definition in PROMMTT patients: the impact of resuscitation on the incidence of hypoxemia. Journal of Trauma and Acute Care Surgery 75, S61-67.
Rogers, T.S. & Fung, M.K. (2016) Permanently removing AB red blood cells from inventory: a case for conserving scarce AB plasma. Transfusion, 56, 2901-2903.
Seheult, J.N., B. Shaz, M. Bravo, H. Croxon, D. Devine, C. Doncaster, S. Field, P. Flanagan, M. Germain, Y. Gregoire, H. Kamel, M. Karafin, N. Kelting, M. Lewis, C. O'Brien, M.F. Murphy, S. Rossmann, M. Sayers, E. Shinar, M. Takanashi, K. Titlestad, M.H. Yazer and C. Biomedical Excellence for Safer Transfusions (2018). Changes in plasma unit distributions to hospitals over a 10-year period. Transfusion 58, 1012-1020.
Shehata, N., Tinmouth, A., Naglie, G., Freedman, J. & Wilson, K. (2009) ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion, 49, 2442-2453.
Shih, A.W., McFarlane, A. & Verhovsek, M. (2014) Haptoglobin testing in hemolysis: measurement and interpretation. American Journal of Hematology, 89, 443-447.
Shih, A.W., Kolesar, E., Ning, S., Manning, N., Arnold, D.M. & Crowther, M.A. (2015) Evaluation of the appropriateness of frozen plasma usage after introduction of prothrombin complex concentrates: a retrospective study. Vox Sanguinis, 108, 274-280.
Sikora, J., Gregory, J., George, A., Clayton, S., Zou, B., Robinson, M., Mukhtar, F. & Pelletier, J.P. (2018) Soluble antigens in plasma allow mismatched transfusion without hemolysis. Transfusion, 58, 1006-1011.
Sperry, J.L., Guyette, F.X., Brown, J.B. et al. (2018) Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. The New England Journal of Medicine, 379, 315-326.
Spradbrow, J., Cohen, R., Lin, Y. et al. (2016) Evaluating appropriate red blood cell transfusions: a quality audit at 10 Ontario hospitals to determine the optimal measure for assessing appropriateness. Transfusion, 56, 2466-2476.
Stevens, W.T., Morse, B.C., Bernard, A. et al. (2017) Incompatible type A plasma transfusion in patients requiring massive transfusion protocol: outcomes of an Eastern Association for the Surgery of Trauma Multicenter study. Journal of Trauma and Acute Care Surgery, 83, 25-29.
Tedesco, D., Hernandez-Boussard, T., Carretta, E., Rucci, P., Rolli, M., Di Denia, P., McDonald, K. & Fantini, M.P. (2016) Evaluating patient safety indicators in orthopedic surgery between Italy and the USA. International Journal for Quality in Health Care, 28, 486-491.
Yazer, M., Eder, A.F. & Land, K.J. (2013) How we manage AB plasma inventory in the blood center and transfusion service. Transfusion, 53, 1627-1633.
Zeller, M.P., Barty, R., Dunbar, N.M. et al. (2018) An international investigation into AB plasma administration in hospitals: how many AB plasma units were infused? The HABSWIN study. Transfusion, 58, 151-157.
Zielinski, M.D., Johnson, P.M., Jenkins, D., Goussous, N. & Stubbs, J.R. (2013) Emergency use of prethawed group A plasma in trauma patients. Journal of Trauma and Acute Care Surgery, 74, 69-74.
Zielinski, M.D., Schrager, J.J., Johnson, P., Stubbs, J.R., Polites, S., Zietlow, S.P., Jenkins, D.H. & Robinson, B.R. (2015) Multicenter comparison of emergency release group A versus AB plasma in blunt-injured trauma patients. Clinical and Translational Science, 8, 43-47.

Auteurs

S Al Khan (S)

Blood Bank Services, Directorate General of Specialized Medical Care, Ministry of Health, Muscat, Oman.

K Rosinski (K)

Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.

T Petraszko (T)

Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Canadian Blood Services, Vancouver, British Columbia, Canada.

P Dawe (P)

Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.
Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.

B W Hwang (BW)

Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.

L Sham (L)

Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.

M Hudoba (M)

Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

K Roland (K)

Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

A W Shih (AW)

Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH